WO2001097860A3 - Produits pharmaceutiques pour l'imagerie de troubles angiogeniques - Google Patents

Produits pharmaceutiques pour l'imagerie de troubles angiogeniques Download PDF

Info

Publication number
WO2001097860A3
WO2001097860A3 PCT/US2001/020108 US0120108W WO0197860A3 WO 2001097860 A3 WO2001097860 A3 WO 2001097860A3 US 0120108 W US0120108 W US 0120108W WO 0197860 A3 WO0197860 A3 WO 0197860A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceuticals
combination therapy
imaging
angiogenic disorders
treatment
Prior art date
Application number
PCT/US2001/020108
Other languages
English (en)
Other versions
WO2001097860A2 (fr
Inventor
Milind Rajopadhye
D Scott Edwards
John A Barrett
Alan P Carpenter Jr
Stuart J Heminway
Shuang Liu
Prahlad Singh
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Priority to CA002413328A priority Critical patent/CA2413328A1/fr
Priority to JP2002503343A priority patent/JP2005538030A/ja
Priority to AU2001268710A priority patent/AU2001268710A1/en
Priority to EP01946697A priority patent/EP1311302A2/fr
Publication of WO2001097860A2 publication Critical patent/WO2001097860A2/fr
Publication of WO2001097860A3 publication Critical patent/WO2001097860A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A61K51/1251—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

L'invention concerne des composés de formule (I):(Q)d-Ln-Ch, (I):utiles pour le diagnostic et le traitement de cancer en thérapie de combinaison chez un patient. Elle concerne des composés utiles dans le traitement de l'arthrite rhumatoïde. Les produits pharmaceutiques sont constitués d'une entité de ciblage qui se lie à un récepteur qui est régulé positivement durant l'angiogénèse, éventuellement d'un groupe de liaison, et d'un radio-isotope efficace sur le plan thérapeutique ou d'une entité à imagerie efficace sur le plan du diagnostic.
PCT/US2001/020108 2000-06-21 2001-06-21 Produits pharmaceutiques pour l'imagerie de troubles angiogeniques WO2001097860A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002413328A CA2413328A1 (fr) 2000-06-21 2001-06-21 Produits pharmaceutiques pour l'imagerie de troubles angiogeniques
JP2002503343A JP2005538030A (ja) 2000-06-21 2001-06-21 組み合わせ療法での使用のための血管新生障害の画像診断用医薬
AU2001268710A AU2001268710A1 (en) 2000-06-21 2001-06-21 Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy
EP01946697A EP1311302A2 (fr) 2000-06-21 2001-06-21 Produits pharmaceutiques pour l'imagerie de troubles angiogeniques

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21320600P 2000-06-21 2000-06-21
US60/213,206 2000-06-21

Publications (2)

Publication Number Publication Date
WO2001097860A2 WO2001097860A2 (fr) 2001-12-27
WO2001097860A3 true WO2001097860A3 (fr) 2003-02-27

Family

ID=22794144

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/020108 WO2001097860A2 (fr) 2000-06-21 2001-06-21 Produits pharmaceutiques pour l'imagerie de troubles angiogeniques

Country Status (5)

Country Link
EP (1) EP1311302A2 (fr)
JP (1) JP2005538030A (fr)
AU (1) AU2001268710A1 (fr)
CA (1) CA2413328A1 (fr)
WO (1) WO2001097860A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9295737B2 (en) 2002-03-01 2016-03-29 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US9408926B2 (en) 2002-03-01 2016-08-09 Bracco Suisse S.A. KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US9446155B2 (en) 2002-03-01 2016-09-20 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US11844783B2 (en) 2010-01-28 2023-12-19 Eagle Pharmaceuticals, Inc. Formulations of bendamustine

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
CN1356913A (zh) 1998-12-18 2002-07-03 杜邦药品公司 玻连蛋白受体拮抗剂药物
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
MXPA02012750A (es) * 2000-06-21 2004-07-30 Bristol Myers Squibb Pharma Co Compuestos farmaceuticos antagonistas del receptor de la vitronectina para su uso en terapia de combinacion.
WO2001097861A2 (fr) * 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Agents pharmaceutiques antagonistes du recepteur de la vitronectine destines a etre utilises dans une therapie combinee
CA2448562A1 (fr) * 2001-05-31 2002-12-05 Miravant Pharmaceuticals, Inc. Agents de photosensibilisation tetrapyrroliques metalliques destines a la therapie photodynamique
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
ES2398393T3 (es) * 2002-03-01 2013-03-15 Dyax Corp. Péptidos de unión a KDR y a VEGF/KDR y su uso en diagnóstico y terapia
US9957293B2 (en) 2006-08-23 2018-05-01 Yeda Research And Development Company Ltd. Conjugates of RGD peptides and porphyrin or (bacterio)chlorophyll photosynthesizers and their uses
WO2008090731A1 (fr) 2007-01-23 2008-07-31 Pola Pharma Inc. Procédé de production de dérivé de 2-nitro-imidazole
EP3101012A1 (fr) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft Nouveaux composés de chélate de gadolinium pour une utilisation dans l'imagerie par résonance magnétique
KR101769911B1 (ko) 2015-11-09 2017-08-21 포항공과대학교 산학협력단 신규한 항암제로서 Skp2 저해제
EP3544964B1 (fr) 2016-11-28 2020-06-17 Bayer Pharma Aktiengesellschaft Composés de chélate de gadolinium à relaxivité élevée pour utilisation dans l'imagerie par résonance magnétique
AU2019382881A1 (en) 2018-11-23 2021-05-20 Bayer Aktiengesellschaft Formulation of contrast media and process of preparation thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999013329A1 (fr) * 1997-09-10 1999-03-18 The Burnham Institute Procedes relatifs a l'identification de molecules capables de rallier des systemes vasculaires angiogeniques dans les tumeurs
WO1999058162A2 (fr) * 1998-03-31 1999-11-18 Du Pont Pharmaceuticals Company Produits pharmaceutiques pour l'imagerie de troubles angiogenes
WO2002004030A2 (fr) * 2000-07-06 2002-01-17 Bristol-Myers Squibb Pharma Company Compositions radiopharmaceutiques stables et procedes de fabrication de ces compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999013329A1 (fr) * 1997-09-10 1999-03-18 The Burnham Institute Procedes relatifs a l'identification de molecules capables de rallier des systemes vasculaires angiogeniques dans les tumeurs
WO1999058162A2 (fr) * 1998-03-31 1999-11-18 Du Pont Pharmaceuticals Company Produits pharmaceutiques pour l'imagerie de troubles angiogenes
WO2002004030A2 (fr) * 2000-07-06 2002-01-17 Bristol-Myers Squibb Pharma Company Compositions radiopharmaceutiques stables et procedes de fabrication de ces compositions

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"CILENGITIDE//ONCOLYTIC ANGIOGENESIS INHIBITOR INTEGRIN ALPHAVBETA3,ALPHAVBETA5 ANTAGONIST", DRUGS OF THE FUTURE, BARCELONA, ES, vol. 7, no. 25, 2000, pages 674 - 678, XP008002380, ISSN: 0377-8282 *
BURKE P A ET AL: "COMBINED MODALITY RADIOIMMUNOTHERAPY//PROMISE AND PERIL", CANCER, AMERICAN CANCER SOCIETY, PHILADELPHIA, PA, US, vol. SUPPL. 4, no. 94, 15 February 2002 (2002-02-15), pages 1320 - 1331, XP008001988, ISSN: 0008-543X *
DENARDO S J ET AL: "NEOVASCULAR TARGETING WITH CYCLIC RGD PEPTIDE (CRGDF-ACHA) TO ENHANCE DELIVERY OF RADIOIMMUNOTHERAPY", CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, LIEBERT, US, vol. 15, no. 1, February 2000 (2000-02-01), pages 71 - 79, XP000925000 *
LIU S ET AL: "90Y AND 177LU LABELING OF A DOTA-CONJUGATED VITRONECTIN RECEPTOR ANTAGONIST USEFUL FOR TUMOR THERAPY", BIOCONJUGATE CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 4, no. 12, July 2001 (2001-07-01), pages 559 - 568, XP001066363, ISSN: 1043-1802 *
WAES1 VAN C ET AL: "EFFECTS OF THE NOVEL ALPHAV INTEGRIN ANTAGONIST SM256 AND CIS-PLATINUM ON GROWTH OF MURINE SQUAMOUS CELL CARCINOMA PAM LY8", INTERNATIONAL JOURNAL OF ONCOLOGY, EDITORIAL ACADEMY OF THE INTERNATIONAL JOURNAL OF ONCOLOGY,, GR, vol. 16, no. 6, 2000, pages 1189 - 1195, XP000925238, ISSN: 1019-6439 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9295737B2 (en) 2002-03-01 2016-03-29 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US9381258B2 (en) 2002-03-01 2016-07-05 Bracco Suisse S.A. Targeting vector-phospholipid conjugates
US9408926B2 (en) 2002-03-01 2016-08-09 Bracco Suisse S.A. KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US9446155B2 (en) 2002-03-01 2016-09-20 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US11844783B2 (en) 2010-01-28 2023-12-19 Eagle Pharmaceuticals, Inc. Formulations of bendamustine

Also Published As

Publication number Publication date
WO2001097860A2 (fr) 2001-12-27
CA2413328A1 (fr) 2001-12-27
JP2005538030A (ja) 2005-12-15
EP1311302A2 (fr) 2003-05-21
AU2001268710A1 (en) 2002-01-02

Similar Documents

Publication Publication Date Title
WO2001098294A3 (fr) Produits pharmaceutiques d'antagonistes recepteurs de la vitronectine utilises en polytherapie
WO2001097860A3 (fr) Produits pharmaceutiques pour l'imagerie de troubles angiogeniques
WO2001097861A3 (fr) Agents pharmaceutiques antagonistes du recepteur de la vitronectine destines a etre utilises dans une therapie combinee
WO1999058162A3 (fr) Produits pharmaceutiques pour l'imagerie de troubles angiogenes
WO2000035492A3 (fr) Medicaments antagonistes du recepteur de la vitronectine
WO2002026776A3 (fr) Composés à base de peptides
WO1998018497A3 (fr) Agents de contraste
CA2249320A1 (fr) Anticorps humanises glycosyles specifiques des lymphocytes b
EP1238985A4 (fr) Anticorps humain de transplantation d'une region de determination de la complementarite agissant contre le ganglioside gd3, et derives dudit anticorps
WO2000035887A3 (fr) Medicaments antagonistes du recepteur de la vitronectine
MXPA04003439A (es) Compuestos de maleimida 3,4 disustituidos como antagonistas de receptor de quimiocina cxc.
WO2002042462A3 (fr) Agents therapeutiques et methodes d'utilisation de ces agents therapeutiques pour traiter une maladie amyloidogenique
IL173029A0 (en) Imaging agents
MXPA03009644A (es) Grupos azabiciclicos sustituidos para el tratamiento de enfermedades.
BRPI0011856B8 (pt) agonistas de receptor a2a de n-pirazol
EP1372741A4 (fr) Imagerie de morpholino et therapie
DK0841949T3 (da) Anvendelse af saccharid-konjugater
WO2001097848A3 (fr) Agents pharmaceutiques antagonistes du recepteur de vitronectine, a utiliser en polytherapie
WO2002051301A3 (fr) Agent de contraste de rayons x a base de fullerene (c60) destine a l'imagerie diagnostique
WO2000035488A3 (fr) Medicaments antagonistes du recepteur de la vitronectine
BR0010802A (pt) Antagonistas de receptor il-8
WO2005044313A3 (fr) Composes pharmaceutiques
EP1293214A3 (fr) Antagonistes du LTB4 et produits radiopharmaceutiques pour l'imagerie de l'infection et l'inflammation
AU4418400A (en) Treatment, imaging and diagnosis of disease using an agent which binds alfa5-integrin
WO2000076457A3 (fr) Antagonistes du recepteur il-8

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2002 503343

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2413328

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001946697

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001946697

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001946697

Country of ref document: EP